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Abstract: Background and aim: Oral mesalazine and sulfasalazine (SASP) are key drugs for treating
ulcerative colitis (UC). The efficacy of switching from one of the several mesalazine formulations
to another is largely unknown. This study assessed the efficacy of switching among three types
of mesalazine formulation and SASP for UC therapy. Methods: UC patients receiving high-dose
mesalazine/SASP who switched to other formulations due to disease activity were considered eligible.
Efficacy was evaluated 2, 6, and 12 months after switching. Results: A total of 106 switches in
88 UC patients were analyzed. The efficacy at 2 months after switching was observed in 23/39
(59%) cases from any mesalazine formulation to SASP, in 18/55 (33%) cases from one mesalazine to
another, and in 2/12 (17%) cases from SASP to any mesalazine formulation. Nine of 43 effective cases
showed inefficacy or became intolerant post-switching. Delayed efficacy more than two months
after switching was observed in four cases. Steroid-free remission was achieved in 42/106 (39%)
cases—within 100 days in 35 of these cases (83%). Conclusions: Switching from mesalazine to SASP
was effective in more than half of cases. The efficacy of switching between mesalazine formulations
was lower but may be worth attempting in clinical practice from a safety perspective.
Keywords: ulcerative colitis; salicylates; mesalazine; sulfasalazine
1. Introduction
Ulcerative colitis (UC) is a chronic idiopathic disorder characterized by manifestations such as
rectal bleeding, diarrhea, abdominal pain, a fever, anemia, and loss of body weight. [1]. Several
etiologies of this disease have been found, but it is still difficult to cure completely. Therefore, better
disease control with continuation of adequate therapies is important. There are various medications
for UC, such as 5-aminosalicylic acids, thiopurines, corticosteroids, calcineurin inhibitors, anti-tumor
necrosis factor (TNFα) antibodies, anti-α4β7integrin antibodies, and Janus kinase inhibitors [2,3].
These medications, however, are not always effective in UC patients, and some show a loss of response
despite initial efficacy. In this regard, physicians must administer these agents carefully to UC patients.
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Oral mesalazine and sulfasalazine (SASP) are first-choice drugs for treating mild-to moderate UC.
In addition, these agents are useful as both induction therapy and maintenance therapy [4,5] and show
sufficient safety with long-term usage. In the early days of UC treatment, only SASP was available.
SASP consists of a mesalazine and a sulfapyridine molecule bound by an azo bond, which is cleaved
upon exposure to colonic bacteria. Systemic absorption of sulfapyridine induces many of the adverse
effects associated with sulfasalazine [6].
In this situation, new formulations containing only the mesalazine component have been developed.
However, uncoated mesalazine is readily absorbed in the upper jejunum and unable to reach the colon in
therapeutic concentrations [7,8]. Studies on alternative mesalazine delivery systems have consequently
resulted in several formulations of oral mesalazine being developed. In Japan, for example, three
types of mesalazine formulation have been approved for treatment of UC: time-dependent mesalazine
(Pentasa), pH-dependent mesalazine (Asacol), and once-daily multi-matrix system (MMX) mesalazine
(Lialda).
Comparisons of the efficacy among these three formulations have been reported. However,
studies with fair comparisons are scarce because the doses of comparative mesalazine formulations are
sometimes different (e.g., 2.25 g/day of Pentasa vs. 3.6 g/day of Asacol). Notably, in the few studies
using similar doses of different types of mesalazine formulation (3 g/day of pH-dependent mesalazine
vs. 3 g/day of time-dependent mesalazine [9] and 2.4 g/day of MMX mesalazine vs. 2.25 g/day of
time-dependent mesalazine [10]), an equivalent efficacy and safety were observed in mild to moderately
active UC patients.
In addition, comparisons between mesalazine and SASP have also been reported. However,
the equivalent doses between mesalazine and SASP are uncertain, so the fairness of those comparisons
is unclear. Furthermore, the efficacy of switching between mesalazine formulations and SASP has
scarcely been reported. Yoshino et al. [11] reported the efficacy of SASP treatment for UC patients
who relapsed despite the oral administration of >4 g/day time-dependent mesalazine or 3.6 g/day
of pH-dependent mesalazine and showed that 69.4% of 36 refractory-UC patients achieved clinical
remission after initiating treatment with SASP. However, few reports have described the efficacy of
switching from one mesalazine formulation to another.
The efficacy of switching between high-dose mesalazine/SASP is a clinical question with great
interest in real clinical practice, as patients in whom high-dose mesalazine/SASP is insufficiently
effective may be switched to immunosuppressive agents or biologics that are likely to be accompanied
by adverse events and a high expense. However, reports regarding this issue are scarce.
Therefore, we investigated the short- and long-term efficacy of switching among mesalazine/SASP
formulations in UC patients who had already received high-dose mesalazine/SASP.
2. Methods
2.1. Patients
Eligible subjects were UC patients who had switched oral mesalazine/SASP formulations at
Okayama University Hospital between January 2006 and March 2019 and had been followed for
>12 months after the switch. Patients who had received the highest dose of mesalazine formation or
SASP approved in Japan (4 g/day for time-dependent mesalazine (Pentasa), 3.6 g/day for pH-dependent
mesalazine (Asacol), and 4.8 g/day for once-daily MMX mesalazine(Lialda)) were included. Patients
who had been administered ≥3 g SASP/day were also considered eligible.
However, cases with switching of mesalazine/SASP due to reasons other than therapy
intensification (e.g., adverse events or the patient’s request) were not included. In addition, cases
starting other therapies within a certain period before the switching were also excluded. The
intervals allowed before switching were more than two weeks for topical mesalazine, corticosteroids,
anti-TNF agents, tacrolimus, or cytapheresis and more than four weeks for immunomodulators
(azathioprine/mercaptopurine).
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In patients who experienced multiple episodes of mesalazine/SASP switching, each episode was
included if the evaluation of the prior episode was finished. Therefore, 16 patients with 2 episodes
were included, as was 1 patient with 3 episodes.
The choice of formulation at the switch depended on each physician’s preference. In principle,
SASP was considered when high-dose mesalazine was insufficient. However, SASP was contraindicated
in a considerable number of patients due to their history or concern regarding adverse effects (e.g., male
infertility); thus, switching between mesalazine formulations was relatively frequent. For switching
between mesalazine formulations or from SASP to mesalazine, the prescription of the maximum
dose of one formulation was immediately changed to a prescription of the maximum dose of another
formulation. For switching from mesalazine to SASP, the dose of SASP was gradually increased with
the gradual decrease in the dose of mesalazine over a period of up to six weeks if adverse events
associated with SASP, such as headache and nausea, were of concern. In principle, patients who
underwent switching received a high dose of mesalazine or SASP for 12 months or longer after the
switch, because these patients were considered to be likely to relapse if the doses of these agents were
reduced, even after an effective switch.
2.2. Evaluated Outcomes
The efficacy was evaluated at 2, 6, and 12 months after switching. The clinical activity was
evaluated using a two-item patient-reported outcome (PRO2), consisting of a rectal bleeding subscore
(RBS) and stool frequency subscore (SFS), [12] extracted from the Mayo score [13]. The clinical courses
were classified as remission, improvement, and inefficacy. The definitions were as follows: remission
occurred when both the RBS and SFS were 0, improvement occurred when the RBS and/or SFS had
decreased but not reached remission, and inefficacy occurred when neither remission nor improvement
had been achieved. Both remission and improvement were taken to indicate “efficacy.” In addition,
the addition of other therapies or escalation of concomitant drugs prior to the evaluation time points
was considered to indicate “inefficacy.” The reduction of concomitant drugs in association with
symptom improvement was allowable. The PRO2 results were confirmed by another activity index
(Lichtiger clinical activity index [14], Figure S1).
Steroid-free remission was defined as an achievement of steroid-free remission after the switching
of mesalazine formulations without additional therapy. A quantitative fecal immunochemical test
(FIT) was performed at each patient visit as a marker of mucosal healing. A negative FIT result
(<100 ng/mL) can predict mucosal healing (Mayo endoscopic score 0) with 92–95% sensitivity and
62–71% specificity [15–17]. The FIT was performed with the OC-Sensor DIANA (Eiken Chemical,
Tokyo, Japan).
This single-center retrospective observational study was approved by the institutional review
board of Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences,
and there were no conflicts of interest or sponsors of this study (IRB approval number: 1806-036).
2.3. Statistical Analyses
The efficacy of switching formulations was compared using Fisher’s exact test. p-values < 0.05
were considered statistically significant. The times to steroid-free remission were analyzed via the
Kaplan–Meier method. The statistical analyses were performed using the JMP pro software program,
ver. 14 (SAS Institute, Cary, NC, USA).
3. Results
3.1. Patient Characteristics
The data of 282 switching cases in 180 UC patients were collected, and 106 cases in 88 UC patents
were eligible for our analysis (Figure 1). The clinical characteristics of the analyzed patients are
summarized in Table 1. The median PRO2 was 2, suggesting that the disease activity of switching
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candidates was not very high. Figure 2 shows the details of the mesalazine formulations/SASP before
and after switching. Before switching, time-dependent mesalazine, pH-dependent mesalazine, and
SASP were prescribed to 46, 48, and 12 patients, respectively. No patients were administered once-daily
MMX mesalazine before switching. After switching, the numbers of patients with time-dependent
mesalazine, pH-dependent mesalazine, once-daily MMX mesalazine, and SASP were 11, 27, 29, and
39, respectively.
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Table 1. Characteristics of the study population.
Patients 88
Gender
Male/Female 48/40
Location of disease
Pancolitis/Left-sided/Proctitis 58/26/4
Median (IQR) age at diagnosis, years 30 (18–44)
Median (IQR) disease duration, years 10 (7–16)
Median (IQR) age at the switching, years 38 (26–50)
Switching of mesalazine/SASP formulations 106
Median (IQR) PRO2 2 (2–3)
Formulations of mesalazine or SASP before switch
Time-dependent/pH-dependent/once-daily MMX/SASP 46/48/0/12
Formulations of mesalazine or SASP after switch
Time-dependent/pH-dependent/once-daily MMX/SASP 11/27/29/39
Concomitant drugs
Oral corticosteroid 22
Topical corticosteroid 15
Immun omodulator 51
Tacrolimus 17
Anti-TNFα agent 4
IQR: interquartile range; PRO2: two-item patient-reported outcome; SASP: sulfasalazine; MMX: multi-matrix system.
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3.2. Short-Term Efficacy of Switching
The short-term efficacy was evaluated two months after switching. Of the 39 cases of switching
from any mesalazine formulation to SASP, fficacy was observed in 59% of cases (2 /39), which included
11 (28%) cases in remission and 12 (31%) cases w th improvement. Intolerance to SASP was observed
i 8 (20%) cases (Figure 3A).
Of the 55 cases of switching from any mesalazine formulation to another, efficacy was observed in
33% of cas s (18/55), which included 13 (23%) c ses in remission a d 5 (9%) cas s with impr vement.
Two-thirds of those switching showed inefficacy or intolerance (Figure 3B).
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Figure 3. Effectiveness at two months after switching mesalazine/SASP formulations. (A) from any
mesalazine to SASP (n = 39), (B) from one mesalazine to another (n = 55), and (C) from SASP to any
mesalazine (n = 12). SASP: sulfasalazine.
Of the 12 cases of switching from SASP to mesalazine, efficacy was observed in only 2 (17%). All
remaining cases showed inefficacy, with no intolerance observed (Figure 3C). The efficacy of switching
from mesalazine to SASP was si nificantly higher than that of the other types of switching (mesalazine
to mesalazine or SASP to mesalazine) (p = 0.014). The results of the analysis based on each mesalazine
formulatio are shown in Figure S2.
3.3. Long-Term Outcomes of Switching
We examined the changes in the PRO2 at 2, 6, and 12 months after switching (Figure 4). Of
the 23 cases of efficacy at 2 months after switching from mesalazine to SASP, 3 showed inefficacy or
intolerance at ≥6 months, whereas of the 12 cases of improvement at 2 months after switching, 9 (75%)
achieved remission by 12 months after switching. Of the 8 cases with inefficacy at 2 months, 1 (12%)
achieved remission at 6 months (Figure 4A).
Of the 18 cases of efficacy at 2 months after switching between mesalazine formulations, 6 showed
inefficacy or intolerance thereafter, whereas of the 5 cases of improvement at 2 months, 2 (40%)
achieved remission by 6 months. Of the 30 cases that showed inefficacy at 2 months, 2 (6.6%) achieved
improvement or remission at 6 months (Figure 4B).
Two cases of efficacy at 2 months after switching from SASP to mesalazine continued to show
efficacy through 12 months after switching. Of the 10 cases that showed inefficacy at 2 months, 1 (10%)
achieved remission by 6 months (Figure 4C). Thus, efficacy was mostly observed within 2 months after
switching, and 34/43 (79%) retained efficacy through 12 months.
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3.4. Achievement of Steroid-Free Remission after Switching between Mesalazine Formulations and SASP
Because more than one-third of our cases received oral and/or topical corticosteroids at the time
of switching, the achievement of steroid-free remission was evaluated (Figure 5A). At 12 months after
switching, steroid-free remission was achieved in 23/39 (59%) of subjects switching from mesalazine
J. Clin. Med. 2019, 8, 2109 8 of 12
to SASP, in 17/55 (30%) of subjects switching from mesalazine to another mesalazine, and in 2/12
(17%) of subjects switching from SASP to mesalazine. The median (interquartile range) of days to
the achievement of steroid-free remission was 56 (39–87), 61 (42–91), and 35 (21–49) days in the
groups switching from mesalazine to SASP, from mesalazine to another mesalazine, and from SASP
to mesalazine, respectively. Of the 42 cases with steroid-free remission, 35 (83%) achieved it within
100 days.
In the present study, the FIT was used as a surrogate marker of the achievement of mucosal
healing. Figure 5B showed the days to achievement of both steroid-free remission and negative FIT
after switching oral mesalazine/SASP formulations. In this analysis, four cases that had negative FIT
at switching were excluded. Both steroid-free remission and negative FIT results were achieved in
20/36 (55%) of subjects switching from mesalazine to SASP, 16/54 (29%) of subjects switching from
mesalazine to another mesalazine, and 2/12 (17%) of subjects switching from SASP to mesalazine,
respectively. Of the 41 patients with steroid-free remission, 38 (92%) achieved both steroid-free
remission and FIT negative results. The median (interquartile range) of days to the achievement of
both steroid-free remission and FIT negative results was 77 (57–134), 81 (52–117), and 217 (168–266)
days in the groups switching from mesalazine to SASP, from mesalazine to another mesalazine, and
from SASP to mesalazine, respectively. The time lag between the achievement of steroid-free remission
and the achievement of negative FIT results suggests that mucosal healing occurs after the achievement
of clinical remission. The endoscopic findings and FIT results from two cases are shown in Figure S3.
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(A) Days to steroid-free remission. Red line: from any mesalazine to SASP (n = 39); green line: fro one
mesalazine to another ( = 55); blue line: from SASP to any mesalazine (n = 12). (B) t steroid-free
remission and neg tive FIT. Red lin : from any mesalazine to SAS 36); green line: fr m one
mesalazine to an ther (n = 54); blue line: fro S t y esalazine (n = 12). Four cases with
negative FIT results at switching were excluded. FIT, fecal immunochemical test; SASP: sulfasalazine.
4. Discus ion
The current study demonstrates the efficacy of switching mesalazine/SASP for active UC patients
despite the administration of high doses of these agents. Efficacy was observed in 23 (59%) of 39 cases
with switching from mesalazine to SASP, 18 (33%) of 55 cases with switching between mesalazine
formulations, and 2 (17%) of 12 cases with switching from SASP to mesalazine. The efficacy of switching
was generally observed within two months, and most patients who responded to switching achieved
steroid-free re ission.
Oral mesal zine in its uncoated for is mostly absorb d b the mall intestine, with very little
active substa ce re ching the colorec um, and the drug delivery sys ems of vari us for ulations
that are currently availa le have been optimized to allow the drugs to reach the affected colorectum
and minimize systemic absorption [6]. At present, three types of formulation of oral esalazine are
available in Japan: time-dependent release mesalazine (Pentasa), pH-dependent release mesalazine
(Asacol), and once-daily MMX mesalazine (Lialda).
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The time-dependent formulation consists of mesalazine microspheres encapsulated in an
ethylcellulose semipermeable membrane. This structure allows the time- and moisture-dependent
release of the active drug, independent of the luminal pH. Mesalazine is theoretically distributed
gradually throughout the gastrointestinal tract from the duodenum to the rectum [18]. The
pH-dependent formulation encapsulates the active substance in an enteric coat in order to regulate the
site of drug release. The coating consists of an enteric resin film designed to dissolve at pH 7, therefore
preventing premature disintegration in the stomach and proximal small bowel. Once-daily MMX is a
once-daily formulation of mesalazine with a multi-matrix system. Mesalazine is incorporated into
a lipophilic matrix, which is in turn dispersed within a hydrophilic matrix. The tablet is enterically
coated and dissolves in the terminal ileum at approximately pH 6.8. The hydrophilic matrix is exposed
to intestinal fluid and swells to form a viscous gel mass. This viscous gel potentiates slow diffusion of
the active substance from the tablet core, thereby enabling a slow, controlled release of mesalazine
throughout the entire length of the colon [19].
Although several reports have compared the efficacy among mesalazine formulations, few have
compared the efficacy at equivalent doses. Gibson et al. [9] performed a randomized double-blind
trial that showed that 3 g/day of pH-dependent mesalazine and 3 g/day of time-dependent mesalazine
achieved comparable rates of clinical remission after 8 weeks. In contrast, Ito et al. [20] reported the
noninferiority of 2.4 g/day of pH-dependent mesalazine to 2.25 g/day of time-dependent mesalazine.
They also reported that 2.4 g/day of pH-dependent mesalazine was significantly more effective
than a placebo in patients with proctitis-type disease, but 2.25 g/day of time-dependent mesalazine
was not. Prantera et al. [21] compared 2.4 g/day of once-daily MMX mesalazine to 2.4 g/day of
pH-dependent mesalazine as maintenance therapy in 331 patients with left-side UC. After 12 months,
the two formulations were comparable in maintaining clinical and endoscopic remission based on a
clinician’s assessment (60.9 and 61.7%, respectively). Thus, the most desirable formulation is currently
undetermined in terms of efficacy and safety.
Studies that have shown the efficacy of switching between mesalazine formulations with equivalent
dose are also scarce. For example, Kawashima et al. [22] reported the efficacy of 3.6 g/day of
pH-dependent mesalazine for UC patients with mild to moderate activity who show resistance to
2.25 g/day of time-dependent mesalazine. Wong et al. [23] reported that 9 UC patients with endoscopic
evidence of active disease, despite treatment with 2.4 g/day of pH-dependent mesalazine switched to
4.0 g/day of time-dependent mesalazine. Definite conclusions cannot be elicited from such unbalanced
switching conditions.
In the present study, switching was performed between the maximum doses of each mesalazine
formulation. The efficacy at 2 months after switching to time-dependent mesalazine, pH-dependent
mesalazine, and once-daily MMX mesalazine was 2/7 (29%) of cases, 6/22 (27%) of cases, and 10/26
(38%) of cases, respectively. Switching to MMX mesalazine may thus be slightly more effective
than switching to time-dependent mesalazine or pH-dependent mesalazine, although there was no
significant difference. However, intolerance to MMX mesalazine was more frequent than it was to
other formulations (0% for Pentasa, 5% for Asacol, and 23% for Lialda). The adverse events associated
with switching to once-daily MMX mesalazine included abdominal discomfort, rash, cough, renal
function disorder, and liver function disorder. Both these favorable and unfavorable effects may be
due in part to the dose of MMX mesalazine (4.8 g/day) being higher than that of other formulations
(Pentasa: 4 g/day; Asacol: 3.6 g/day). It is also possible that a special coating associated with MMX
technology was responsible.
Regarding switching from one mesalazine to SASP, Yoshino et al. [11] reported the efficacy of
switching to SASP (n = 25) or adding SASP (n = 11) in 36 UC patients refractory to mesalazine
(>4 g/day of time-dependent mesalazine or >3.6 g/day of pH-dependent mesalazine), with 25 achieving
clinical remission. In the current study, switching from mesalazine to SASP was effective in 59% of
patients. These results were in line with those of previous reports [11,24]. The usefulness of SASP for
inducing and maintaining remission in UC patients is well established [25,26]. However, because less
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mesalazine is included in SASP than in the same dose of other mesalazine formulations, the efficacy
of SASP might also be exerted by other mechanisms than the release of mesalazine in the colon.
Indeed, Fujiwara et al. reported that SASP might inhibit the T-cell-dependent antibody response partly
through the suppression of IL-2 production [27,28]. Matastic et al. further showed that SASP inhibited
the maturation of human dendritic cells [29], and Rodenburg et al. indicated that SASP inhibited
TNF-alpha expression in macrophages by inducing apoptosis [30].
However, adverse events are more frequent when using SASP than when using other mesalazine
formulations. A meta-analysis demonstrated that 29% of patients treated with SASP experienced
adverse events compared with 14% of those using other mesalazine agents (relative risk = 0.48, 95%
confidence interval: 0.36–0.63) [4]. Both non-dose-dependent and dose-dependent adverse events
have been reported in SASP. Dose-dependent adverse events include headache, nausea, and fatigue.
When dose-dependent adverse events occur, dose reduction of formulations is a useful method of
resolving the issue. Therefore, in the present study, the dose of SASP was gradually increased at
switching when adverse events of SASP were of concern. However, despite this approach, 25% of
patients who switched to SASP showed intolerance. Based on the results of our study, time-dependent
mesalazine or pH-dependent mesalazine should be considered first, as these formulations cause fewer
adverse events than SASP or MMX mesalazine. When mild activity persists despite a sufficient dose of
mesalazine formulation, switching to SASP should be considered.
One strength associated with this study is its inclusion of highly refractory patients. Indeed, 59
patients were using immunomodulators, tacrolimus, or anti-TNF agents. Although the characteristics
of our patients differed from each other in this context, our results confirmed that switching of
mesalazine/SASP was effective for a variety of UC patients, regardless of concomitant therapy. Of these
refractory patients, 20 (33%) achieved remission simply by mesalamine/SASP switching. However,
more potent and costly therapies with a possible risk of adverse events were required in the remaining
39 switch-ineffective cases (e.g., 13 received new biologics, and 3 received tofacitinib). Safer and less
costly therapies, including Escherichia coli Nissle 1917 [31] and IBD98-M [32], could be applicable in the
treatment of these patients in the future.
Another strength is the evaluation of the long-term effect and steroid-free remission rate following
switching of mesalazine/SASP, as most previous reports have evaluated only the short-term clinical
response. As UC is a long-lasting disease, only short-term efficacy with therapeutics is insufficient.
Furthermore, because most patients who were candidates for switching the mesalazine/SASP
formulation had mild activity, the improvement in symptoms might have been a “placebo effect.”
Therefore, to verify the efficacy of switching in this study, the FIT was used as a biomarker of the
achievement of mucosal healing. These meticulous evaluations improved the reliability of this study
despite the retrospective nature of the analysis.
Several limitations associated with the present study warrant mention. First, this was a
retrospective study with a relatively small number of patients conducted in a single-center setting.
Second, while a considerable number of patients might use generic versions of mesalazine/SASP,
the difference in efficacy between the generic versions and originators could not be determined.
In conclusion, we observed the efficacy of switching of mesalazine/SASP for the induction of
remission in patients with UC, particularly in cases switching from mesalazine to SASP. Switching
mesalazine/SASP may be a viable therapeutic option for UC patients with a relatively low clinical
activity, even after the administration of high doses of these agents.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/12/2109/s1.
Figure S1: Relation between PRO2 and Lichtiger clinical activity index in patients who underwent switch.
PRO2: two-item patient-reported outcome, Figure S2: Effectiveness at two months after switching each type
of mesalazine/SASP formulations. (A) from each type of mesalazine to SASP (n = 39), (B) from each type of
mesalazine to another (n = 55), and (C) from SASP to each type of mesalazine (n = 12). SASP, sulfasalazine; MMX,
multi-matrix Figure S3: Endoscopic findings and FIT results in 2 cases. FIT: fecal immunochemical test. Table S1:
Details of intolerance.
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